MISSISSAUGA, Ontario, May 22, 2026
Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation for Gazyva® (obinutuzumab) for the treatment of adults with active lupus nephritis receiving standard therapy. The recommendation marks another major regulatory milestone for Gazyva following its Health Canada approval earlier in 2026 and moves the therapy closer to broader public reimbursement access across Canadian provinces and territories.
Phase 3 REGENCY Data Supported Recommendation
The CDA-AMC recommendation was supported by data from the Phase 3 REGENCY study, which evaluated Gazyva in combination with standard therapy including mycophenolate mofetil and glucocorticoids. Roche reported that 46.4% of patients treated with Gazyva achieved complete renal response, compared with 33.1% for patients receiving standard therapy alone. The trial also demonstrated statistically significant reductions in corticosteroid use and improved proteinuria outcomes, highlighting the therapy’s potential to better control kidney inflammation and slow disease progression in lupus nephritis patients.
Gazyva Targets Disease-Causing B Cells in Lupus Nephritis
Gazyva is a Type II engineered humanized monoclonal antibody targeting the CD20 protein found on B cells involved in autoimmune activity. In lupus nephritis, abnormal B-cell activity drives persistent inflammation that damages kidney tissue and may ultimately lead to kidney failure. Roche stated that Gazyva works by depleting disease-causing B cells, potentially limiting further kidney injury and delaying progression to end-stage kidney disease requiring dialysis or transplantation. Lupus nephritis affects nearly 40% of people living with systemic lupus erythematosus (SLE), with women disproportionately impacted worldwide.
Advertisement
Public Access Decisions Now Move to Provinces
While CDA-AMC has recommended reimbursement, final decisions regarding public drug plan coverage will be made individually by provincial and territorial healthcare authorities across Canada. Roche Canada stated that it plans to continue working closely with public and private payers to accelerate patient access to Gazyva for adults living with active lupus nephritis. The company emphasized that significant unmet medical need remains despite available therapies, particularly for patients at risk of progressive kidney damage and long-term renal complications.
Source: Roche Canada, press release
